Correction to: Modeling invasive breast cancer: growth factors propel progression of HER2-positive premalignant lesions (Oncogene, (2012), 31, 31, (3569-3583), 10.1038/onc.2011.547)

Correction to: Oncogenehttps://doi.org/10.1038/onc.2011.547, published online 5 December 2011 Following the publication of this article, the authors noted that one of the images shown in Supplementary Figure S5 (triplicate photos of SKBR3 cells treated with various inhibitory agents for 12 days) was inadvertently duplicated. The authors have corrected this unintentional error and present below the correct form of Figure S5. This image correction changed neither image quantification nor the conclusion that transcriptional induction of specific ligands and integrins is essential for EGF-induced invasive growth of HER2-overexpressing mammary cells. (Figure presented.) Supplementary Figure S5: Effects of specific drugs on EGF-induced invasiveness of HER2-overexpressing breast cancer cell lines grown in extracellular matrix: SKBR3 cells were plated in Matrigel^TM and treated without or with EGF for 4 days. Thereafter, the cultures were grown for 8 additional days in the absence or presence of the following agents: an anti-HER2 antibody (Trastuzumab, 25 μg/ml), the dual HER2 and EGFR kinase inhibitor, GW2974 (100 nM), the lysyl oxidase inhibitor, β- aminopropionitrile (BAPN; 200 nM), or a blocking antibody specific to integrin alpha V (25 μg/ml). The phase contrast images were taken on day 12. Scale bar; 100 μm. The original article has been corrected.